Czerniecki
B. Gad SC. Reilly C. Smith AC. Witz G. Phorbol diacetate
inhibits superoxide anion radical production and tumor promotion
by mezerein. Carcinogenesis. 7(10):1637-1641, Oct. 1986.
Czerniecki B.
Witz G. Reilly C. Gad SC. The development of contact hypersensitivity
in mouse skin is suppressed by tumor promoters. Journal of
Applied Toxicology. 8(1):1-8, Feb. 1988.
Ryer-Powder JE. Amoruso
MA. Czerniecki B. Witz G. Goldstein BD. Inhalation
of ozone produces a decrease in superoxide anion radical production
in mouse alveolar macrophages. American Review of Respiratory
Disease. 138(5):1129-1133, Nov. 1988.
Witz G. Czerniecki
BJ. Tumor promoters differ in their ability to stimulate
superoxide anion radical production by murine peritoneal exudate
cells following in vivo administration. Carcinogenesis. 10(5):807-811,
May 1989.
Goldstein BD. Czerniecki
B. Witz G. The role of free radicals in tumor promotion.
Environmental Health Perspectives. 81:55-57, May 1989.
Czerniecki BJ.
Witz G. Arachidonic acid potentiates superoxide anion radical
production by murine peritoneal macrophages stimulated with
tumor promoters. Carcinogenesis. 10(10):1769-1775, Oct. 1989.
Czerniecki BJ.
Witz G. Tumor promoters stimulate the formation of 1,2-diacylglycerol
in murine peritoneal macrophages: a possible mechanism for
stimulating superoxide anion radical production. Cancer Letters.
48(1):29-36, Nov. 15, 1989.
Czerniecki BJ.
Carter C. Rivoltini L. Koski GK. Kim HI. Weng DE. Roros JG.
Hijazi YM. Xu S. Rosenberg SA. Cohen PA. Calcium ionophore-treated
peripheral blood monocytes and dendritic cells rapidly display
characteristics of activated dendritic cells. Journal of Immunology.
159(8):3823-3837, Oct. 15, 1997.
Czerniecki BJ.
Scheff AM. Callans LS. Spitz FR. Bedrosian I. Conant EF. Orel
SG. Berlin J. Helsabeck C. Fraker DL. Reynolds C. Immunohistochemistry
with pancytokeratins improves the sensitivity of sentinel
lymph node biopsy in patients with breast carcinoma. Cancer.
85(5):1098-1103, Mar. 1, 1999.
Reynolds C. Mick R. Donohue
JH. Grant CS. Farley DR. Callans LS. Orel SG. Keeney GL. Lawton
TJ. Czerniecki BJ. Sentinel lymph node biopsy
with metastasis: can axillary dissection be avoided in some
patients with breast cancer?. Journal of Clinical Oncology.
17(6):1720-1726, June 1999.
Bedrosian I. Scheff AM.
Mick R. Callans LS. Bucky LP. Spitz FR. Helsabeck C. Elder
DE. Alavi A. Fraker DF. Czerniecki BJ. 99mTc-human
serum albumin: An effective radiotracer for identi-fying sentinel
lymph nodes in melanoma. Journal of Nuclear Medicine. 40(7):1143-1148,
July 1999.
Koski GK. Schwartz GN.
Weng DE. Czerniecki BJ. Carter C. Gress RE.
Cohen PA. Calcium mobilization in human myeloid cells results
in acquisition of individual dendritic cell-like charac-teristics
through discrete signaling pathways. Journal of Immunology.
163(1):82-92, July 1, 1999.
Koski GK. Schwartz GN.
Weng DE. Gress RE. Engels FH. Tsokos M. Czerniecki
BJ. Cohen PA. Calcium ionophore-treated myeloid cells
acquire many dendritic cell characteristics independent of
prior differentiation state, transformation status, or sensitivity
to biologic agents. Blood. 94(4):1359-1371, Aug. 15, 1999.
Engels FH. Koski GK. Bedrosian
I. Xu S. Luger S. Nowell PC. Cohen PA. Czerniecki
BJ. Calcium signaling induces acquisition of dendritic
cell characteristics in chronic myelogenous leukemia myeloid
progenitor cells. Proceedings of the National Academy of Sciences
of the United States of America. 96(18):10332-10337, Aug.
31, 1999.
Weinstein S. Zuckerman J. Lawton
T. Orel S. Czerniecki BJ. Conant E. Retrospective
review of palpable breast lesions after negative mammography
and sonography. Journal of Women's Imaging 2:15-18, 2000.
Faries MB. Bedrosian I. Reynolds
C. Nguyen HQ. Alavi A. Czerniecki BJ. Active
macromolecule uptake by lymph node antigen-presenting cells:
a novel mechanism in determining sentinel lymph node status.
Annals of Surgical Oncology. 7(2):98-105, Mar. 2000.
Bedrosian I. Faries MB. Guerry
D 4th. Elenitsas R. Schuchter L. Mick R. Spitz FR. Bucky LP.
Alavi A. Elder DE. Fraker DL. Czerniecki BJ.
Incidence of sentinel node metastasis in patients with thin
primary melanoma (< or = 1 mm) with vertical growth phase.
Annals of Surgical Oncology. 7(4):262-7, May 2000.
Bedrosian I. Roros JG. Xu S.
Nguyen HQ. Engels F. Faries MB. Koski GK. Cohen PA. Czerniecki
BJ. Granulocyte-macrophage colony-stimulating factor,
interleukin-2, and interleukin-12 synergize with calcium ionophore
to enhance dendritic cell function. Journal of Immunotherapy.
23(3):311-20, May/June 2000.
Bedrosian I. Reynolds C. Mick
R. Callans LS. Grant CS. Donohue JH. Farley DR. Heller R.
Conant E. Orel SG. Lawton T. Fraker DL. Czerniecki
BJ. Accuracy of sentinel lymph node biopsy in patients
with large primary breast tumors. Cancer. 88(11):2540-2545,
June 1, 2000.
Orel SG. Dougherty CS. Reynolds
C. Czerniecki BJ. Siegelman ES. Schnall MD.
MR imaging in patients with nipple discharge: initial experience.
Radiology. 216(1):248-254, July 2000.
Engels FH. Kreisel D. Faries
MB. Bedrosian I. Koski GK. Cohen PA. Czerniecki BJ.
Calcium ionophore activation of chronic myelogenous leukemia
progenitor cells into dendritic cells is mediated by calcineurin
phosphatase. Leukemia Research. 24(10):795-804, Oct. 2000.
Weinstein SP. Orel SG. Heller
R. Reynolds C. Czerniecki B. Solin LJ. Schnall
M. MR imaging of the breast in patients with invasive lobular
carcinoma. AJR. American Journal of Roentgenology. 176(2):399-406,
Feb. 2001.
Chang JH. Vines E. Bertsch H.
Fraker DL. Czerniecki BJ. Rosato EF. Lawton
T. Conant EF. Orel SG. Schuchter L. Fox KR. Zieber N. Glick
JH. Solin LJ. The impact of a multidisciplinary breast cancer
center on recommendations for patient management: the University
of Pennsylvania experience. Cancer 91(7):1231-1237, Apr. 1,
2001.
Czerniecki BJ.
Cohen PA. Faries M. Xu S. Roros JG. Bedrosian I. Diverse functional
activity of CD83+ monocyte-derived dendritic cells and the
implications for cancer vaccines. Critical Reviews in Immunology
21(1-3):157-178, 2001.
Cohen PA. Peng L. Kjaergaard
J. Plautz GE. Finke JH. Koski GK. Czerniecki BJ.
Shu S. T-cell adoptive therapy of tumors: Mechanisms of improved
therapeutic performance. Critical Reviews in Immunology 21(1-3):215-248,
2001.
Czerniecki BJ.
Bedrosian I. Faries M. Alavi A. Revolutionary impact of lymphoscintigraphy
and intraoperative sentinel node mapping in the clinical practice
of oncology. Seminars in Nuclear Medicine 31(2):158-164, Apr.
2001.
Wildemore JK 4th. Schuchter L.
Mick R. Synnestvedt M. Elenitsas R. Bedrosian I. Czerniecki
BJ. Guerry D 4th. Lessin SR. Elder DE. Bucky LP.
Locally recurrent malignant melanoma characteristics and outcomes:
A single-institution study. Annals of Plastic Surgery 46(5):488-494,
May 2001.
Weinstein SP. Orel SG. Collazzo
L. Conant EF. Lawton TJ. Czerniecki B. Cyclosporin
A-induced fibroadenomas of the breast: Report of five cases.
Radiology 220(2):465-468, Aug. 2001.
Faries MB. Bedrosian I. Xu S.
Koski G. Roros JG. Moise MA. Nguyen HQ. Engels FH. Cohen PA.
Czerniecki BJ. Calcium signaling inhibits
interleukin-12 production and activates CD83(+) dendritic
cells that induce Th2 cell development. Blood 98(8):2489-2497,
Oct. 15, 2001.
Bauer TW. Spitz FR. Callans LS.
Alavi A. Mick R. Weinstein SP. Bedrosian I. Fraker DL. Bauer
TL. Czerniecki BJ. Subareolar and peritumoral
injection identify similar sentinel nodes for breast cancer.
Annals of Surgical Oncology 9(2):169-176, Mar. 2002.
Prabakaran I. Menon C. Xu S.
Gomez-Yafal A. Czerniecki BJ. Fraker DL.
Mature CD83(+) dendritic cells infected with recombinant gp100
vaccinia virus stimulate potent antimelanoma T cells. Annals
of Surgical Oncology 9(4):411-418, May 2002.
Bedrosian I. Schlencker J. Spitz
FR. Orel SG. Fraker DL. Callans LS. Schnall M. Reynolds C.
Czerniecki BJ. Magnetic resonance imaging-guided
biopsy of mammographically and clinically occult breast lesions.
Annals of Surgical Oncology 9(5):457-461, June 2002.
Lee SG. Orel SG. Woo IJ. Cruz-Jove
E. Putt ME. Solin LJ. Czerniecki BJ. Schnall
MD. MR imaging screening of contralateral breast in patients
with newly diagnosed breast cancer: Preliminary results. Radiology
226(3):773-778, Mar. 2003.
Bedrosian I, Schlencker J, Mick
R, Orel S, Schnall M, Reynolds C, Spitz FR, Callans L, Buzby
GP, Rosato EF, Fraker DL, Czerniecki BJ.
Changes in the surgical management of patients with breast
carcinoma based on preoperative magnetic resonance imaging.
Cancer 98(3):468-473, Aug. 1, 2003.
Xu S, Koski GK, Faries MB, Bedrosian
I, Mick R, Maeurer M, Chever, Cohen PA, Czerniecki
BJ. Rapid high efficiency sensitization of CD8 +
T cells to tumor antigens by dendritic cells leads to enhanced
functional avidity and direct tumor recognition through an
IL- 12 dependent mechanism. Journal of Immunology 171(5):2251-2261,
Sept. 1, 2003.
Bedrosian IB, Mick R, Xu S, Nisenbaum
H, Faries M, Zhang P, Cohen PA, Koski G, Czerniecki
BJ. Intranodal administration of peptide-pulsed mature
dendritic cell vaccines results in superior CD8+ T cell function
in melanoma patients. Journal of Clinical Oncology 21(20):3826-3835,
Oct. 15, 2003.
Koski GK, Kariko K, Xu S, Weissman
D, Cohen PA, Czerniecki BJ, Cutting Edge:
Innate immune system discriminates between RNA containing
bacterial versus eukaryotic structural features that prime
for high-level IL-12 secretion by dendritic cells. The Journal
of Immunology, 2004, 172: 3989-3993, 2004.
Gimotty PA, Guerry D, Ming ME,
Elenitsas R, Xiaowei Xu, Czerniecki B, Spitz
F, Schucter L, Elder, D. Thin primary cutaneous malignant
melanoma: A prognostic tree for ten metastasis is more accurate
than AJCC staging. Journal of Clinical Oncology 2004, 22:
3668-3676.
Kesmodel SB, Karakousis GC, Botbyl,
JD, Canter RJ, Lewis RT, Wahl PM, Terhune KP, Alavi, A, Elder
DE, Ming ME, Guerry D, Gimotty PA, Fraker DL, Czerniecki
BJ, Spitz, FR. Mitotic rate as a predictor of sentinel
lymph node positivity in patients with thin melanoma. Annals
of Surgical Oncology 12: 449-458 2005.
Bedrosian, I. Czerniecki
BJ. Change in surgical Management of breast cancer
patients based on preoperative MR imaging Am J Onc Rev, 2004;
3(4):209.
Downes K, Glatt BS, Kanchwala
SK, Mick R, Fraker DL, Fox KR, Solin LJ, Bucky LP, Czerniecki
BJ. Skin-sparing mastectomy and immediate reconstruction
as an acceptable treatment option for high-risk breast cancer
patients. Cancer 2005.
Koski, GK, and Czerniecki
BJ. Combining innate immunity with radiation therapy
for cancer treatment. Clinical Can Res. 2005, 11: 7-11.
Chance B, Nioka S, Zhang J, Conant
EF, Hwang E, Briest SG, Orel SG, Schnall MD, Czerniecki
BJ. Breast Cancer Detection based on incremental
biochemical and physiological properties of breast cancers
a six-year, two-site study. Acad Radiol 2005; 12(8):925-933.
Choe R, Corlu A, Lee K, Durduran
T, Konecky SD, Grosicka-Koptyra M, Arridge S, Czerniecki
BJ, Fraker DL, DeMichele A, Chance B, Rosen M, Yodh
A. Diffuse optical Tomography of breast cancer during neoadjuvant
chemotherapy: a case study in comparison to MRI. Medical Physics
32:1128-1139 2005.
Jackson BM, Kim S, Davidson R,
Schuchter L, Acs G, Czerniecki BJ. Re-operative
sentinel lymph node biopsy: a case report. Clinical Breast
Cancer 6: 530-532 2006.
Durduran, T, Choe R, Yu, G,
Zhou C, Tchou, J, Czerniecki BJ, Yodh, A.
Diffuse optical measurement of blood flow in breast tumors.
Optics Letters 2005, 30:2915-2917.
Somasundaram R, Swoboda R, Caputo
L, Otvos L, Weber B, Volpe P, VanBelle P, Hotz, Elder DE,
Marincola FM, Schuchter, L, Guerry D, Czerniecki BJ,
Herlyn D. HLA-A2-restricted CTL responses to mutated BRAF
peptides in melanoma patients. Cancer Res. 2006; 66:3287-3293.
Karakousis GC, Gimotty PA, Botbyl,
Kesmodel SB, Elder DE, Ming ME, Guerry D, Fraker DL, Czerniecki
BJ, Spitz FR. Predictors of regional nodal disease
in patients with thin melanomas. Annals of Surgical Oncology
13: 533-541 2006.
Kesmodel SB, Canter RJ, Terhune
KP, Bauer TW, Mick R, Rosato EF, Spitz FR, Fraker DL, Alavi
A, Czerniecki BJ. Use of radiotracer for
sentinel lymph node mapping in breast cancer optimizes staging
independent of site of administration. Clinical Nuclear Medicine
31:1-7 2006.
Xu S, Koldovsky U, Xu M, Wang
D, Fitzpatrick E, Son G, Koski G, Czerniecki BJ.
Toll receptor 8 signaling primes myeloid dendritic cells for
high level IL-12 production. Surgery 140:170-178 2006.
Gimotty, PA, Elder DE, Fraker
DL, Botbyl J, Sellers K, Elenitsas R, Ming ME, Schuchter L,
Spitz FR, Czerniecki BJ, Guerry D. Biologically-based
prognostic factors improve risk discrimination in patients
with thin (=1.00) invasive cutaneous melanoms. (Submitted
for Publication).
Mavi A, Urhan M, Yu JQ, Zhuang
H, Houseni M, Cermik TF, Czerniecki B, Schnall
M, Alavi A. Dual time point FDG-PET imaging detects breast
cancer with high sensitivity and correlates well with histologic
subtypes of the lesions. J. Nuclear Medicine 47: 1440-1446
2006.
Zhang T, Somasundarum R, Caputo,
L, VanBelle P, Elder D, Czerniecki B, Hotz
S, Schuchter L, Spitz FR, Klara B, Rani P, Marincola F, Qiu
R, Herlyn D. Preferential Involvement of CX Chemokine Receptor
4 and CX Chemokine Ligand 12 in T-cell migration toward melanoma
cells. Cancer Biology & Therapy (In Press).
Czerniecki BJ,
Xu M, Koski G. Neoadjuvant Therapy for HER-2/neu-expressing
ductal carcinoma in situ using type 1 polarized dendritic
cell vaccines. Breast Diseases: A Yearbook Quarterly 17: 320-323
2007.
Czerniecki BJ,
Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R, Nisenbaum H,
Pasha T, Xu M, Fox KR, Weinstein S, Orel SG, Vonderheide R,
Coukos G, DeMichele A, Araujo L, Spitz FR, Rosen M, Levine
BL, June C, Zhang PJ. Targeting HER-2/neu in early breast
cancer development using dendritic cells with staged IL-12
burst secretion. Cancer Res (In Press).
Roses R, Xu M, Xu S, Koldovsky
U, Son G, Koski GK, Czerniecki BJ. Working
towards the development of cancer vaccines for the treatment
and prevention of breast cancer. Current Cancer Therapy Reviews
(In Press).
Research Publications, non-peer reviewed
Witz G. Czerniecki
BJ. In vivo inhibition by phorbol esters of oxy radical
production by murine peritoneal exudate cells stimulated with
phorbol myristate acetate. Annals of the NY Academy of Science
494:294-295, 1987.
Buell JF. Temeck BK. Czerniecki
BJ. Lubensky IA. Pass HI. Management of thoracic
carcinoid tumors in multiple endocrine neoplasia I population.
Contemporary Surgery 49:200-206, 1996.
Mulvany KP. Prabakaran I. Shuwen
Xu M. Khorrami C. Menon C. Czerniecki BJ.
Fraker DL. Callans LS. Human monocyte-derived dendritic cells
transduced with recombinant adenovirus present melanoma antigen
gp100 to cytotoxic T lymphocytes in vitro. Surgical Forum
50:311-313, 1999.
Abstracts (last 3 years)
Czerniecki BJ.
Xu S. Koski G. IL-12 production by DC enhances CD8 heterodimer
usage and increases functional avidity of anti-tumorCD8+ T
cells. Keystone Symposium, Feb. 2003.
Xu S. Koski GK. Faries M. Bedrosian
I. Mick R. Thomas E. Cheever M. Cohen P. Czerniecki
BJ. IL-12 secreting DC1 induces high functional avidity
tumor recognizing CD8+T cells American Association for Cancer
Researchers 94th Annual Meeting, Washington DC, July 2003.
Koski G. Kariki K. Xu S. Czerniecki
BJ. Human dendritic cells discriminate between RNA
containing eukaryotic versus prokaryotic structural features
that prime for high-level IL-12 secretion. American Association
of Immunologists Annual Meeting, Washington, DC, April 2003.
Kesmodel SB. Karakousis GC. Terhune
KP. Canter RJ. Wahl PM. Gimotty PA. Guerry D. Fraker DL. Czerniecki
BJ. Spitz FR. Mitotic rate as a predictor of sentinel
lymph node positivity in patients with thin melanomas. Society
of Surgical Oncology, Annual Cancer Symposium, March 2004.
Kruper LL. Karakousis GC. Kesmodel
SB. Kumar R. Gimotty PA. Guerry D. Spitz FR. Fraker DL. Alavi
A. Czerniecki BJ. Possible therapeutic role
of sentinel node biopsy in thin (<1.0 mm) melanomas. Society
of Nuclear Medicine, Annual Meeting, June 2004.
Czerniecki BJ,
Koldovsky Uu Xu S, Mick R, Nisenbaum H, Orel S, Fox K, Koski
G. Combining innate and adaptive immunity for the treatment
of breast cancer. International Society of Biological Therapy
Meeting, Alexandria VA. November 2005.
Czerniecki BJ,
Koldovsky U, Xu S, Xu M, Son G, Nissenbaum H, Zhang P, Mick
R, Koski G. Immunoediting Breast Cancer Using HER-2/Neu Pulsed
Autologous Dendritic Cell Vaccines. Presented at the Society
of University Surgeons, San Diego, CA February 2006.
Xu S, Koldovsky U, Xu, M, Son
G, Fitzpatrick E, Wang D, Mick R, Nissenbaum, Zhang P, and
Czerniecki BJ. Type-I polarized HER-2/neu
pulsed dendritic cell vaccines generate anti-tumor CD8+ T
cells despite the presence of antigen specific CD8+ tolerance
in patients with early non-invasive breast cancer. American
Association for Cancer Research, Washington DC April 2006.
Editorials, Reviews, Chapters & Participation
in Committee Reports
Witz G. Czerniecki
BJ. Gad SC. Goldstein BD. In vivo stimulation of
oxy radicals by mouse skin tumor promoters. In Cerrutti P,
Nygaard O, Simic MG (eds): Anticarcinogenesis and Radiation
Protection. New York: Plenum Publ. Co., 1987, 199-205.
Cohen PA. Fowler DH. Kim H. White
RL. Czerniecki BJ. Carter C. Gress RE. Rosenberg
SA. Propagation of mouse and human T cells with defined antigen
specificity and function. In: Vaccines against Virally Induced
Cancers. New York: Wiley & Sons, 1994 (Ciba Foundation
Symposium 187:179-197).
Czerniecki BJ.
Bedrosian I. Tumor deprived peptide vaccines for treatment
of Melanoma. The Melanoma Letter 15(3), 1997.
Czerniecki BJ.
Nguyen H. Glatstein E. Fox K. Treatment of Hodgkin's and Non-Hodgkin's
Lymphoma. Chap. 15 in Torosian MH (ed): Integrated Cancer
Management: Surgery, Medical Oncology and Radiation Therapy.
New York: Marcel-Dekker, 1999, 360-393.
Bedrosian I. Czerniecki
BJ. Tumor biology. In Kreisel D, Krupnick AS, Kaiser
LR (eds): The Surgical Review. Philadelphia: Lippincott, Williams
& Wilkins, 2001, 69-90.
Patents
University of Pennsylvania
Health System and Czerniecki BJ. Method for
isolating dendritic cells: Preparing and activating dendritic
cell rich antigen presenting cells from human peripheral blood.
U.S. Patent awarded January 1997.
Czerniecki
BJ. Tumor reactive cells: Their proliferation and
use in adoptive cellular therapy: Determinations of lymph
nodes enriched in CD4+ T-helper lymphocytes and their proliferation
for use in adoptive immunotherapy. U.S. Patent awarded April
1998.
Czerniecki
BJ. Method for increasing the antigen presenting
ability of leukemia cells. US patent awarded March 2002.
|